Publication:
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.

Loading...
Thumbnail Image

Date

2022-10-11

Authors

Navarro, Natalia
Molist, Carla
Sansa-Girona, Júlia
Zarzosa, Patricia
Gallo-Oller, Gabriel
Pons, Guillem
Magdaleno, Ainara
Guillén, Gabriela
Hladun, Raquel
Garrido, Marta

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in metastasis and provide evidence demonstrating its essentiality for metastatic dissemination in rhabdomyosarcoma and neuroblastoma. However, the most translational advance of this study is to reveal, for the first time, the possibility of reducing metastasis by pharmacological inhibition of ITGA9 with a synthetic peptide simulating a key interaction domain of ADAM proteins, in experimental metastasis models, not only in childhood cancers but also in a breast cancer model.

Description

MeSH Terms

ADAM Proteins
Humans
Integrin alpha Chains
Integrins
Neoplasm Metastasis
Neuroblastoma
Rhabdomyosarcoma

DeCS Terms

CIE Terms

Keywords

Cancer, Dissemination, Paediatric cancer, Progression, Solid tumours

Citation